Video Library
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18).
Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss strategies for addressing patients’ concerns about how combination therapy may impact their activities of daily living and quality of life.
The last 10 to 15 years has seen important advances in the management of advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss how real-world efficacy and safety data influence the conversations they have with their patients with advanced renal-cell carcinoma regarding treatment options.
Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their approach to conversations with patients and families regarding first-line therapy for advanced renal-cell carcinoma. They also describe what resources they share with patients to help them after the initial consultation.
Maintaining quality of life for cancer patients means different things to different cancer patients. However, the conversation starts with helping patients manage their expectations regarding their therapy and how it will impact their quality of life. Please join Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, as they examine the many ways that they collaborate with their oncology team colleagues to assess and review how an individual patient’s treatment regimen is influencing that patient’s quality of life.
The practice of using combinations of drugs in chemotherapy is not new and continues to evolve to include immune checkpoint inhibitors. Drug combinations can be more effective than single-agent therapy and may also reduce the risk of developing resistance. However, combining multiple drugs may increase the risk of drug interactions. Please join Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, as they discuss how they have a conversation with their patients about the benefits and risks of using drug combinations in anticancer therapy.
Although chemotherapy is effective in combating cancer, its full benefits are often not realized because many patients do not take their medications as prescribed. There are many factors that contribute to poor medication adherence, including communication barriers, adverse events, and factors that are related to the therapy, such as prescription of complex drug regimens. Because barriers to medication adherence are complex and varied, solutions to improve adherence must also be multifactorial. Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their best practices to help patients adhere to their chemotherapy regimens.
Helping the patient’s caregiver understand their role in the NSCLC patient’s journey
Addressing common questions from NSCLC patients and their caregivers
Providing psychosocial support and counseling for NSCLC patients and their family
Educating patients about cancer- and treatment-related side effect management
There are currently many online and print resources that you can use to help fulfill your patients’ educational needs. However, nurse navigators and advanced care practitioners can also call upon their training and experience to help patients better understand what they are about to undergo. Please join Laura Wood, RN, MSN, OCN; Virginia Seery, MSN, RN, ANP-BC, AOCNP; and Megan Price, MSN, APRN, FNP-C, as they discuss their best practices for helping patients understand their diagnosis, treatment options, and potential adverse events.
